Group 1 - Company announced a placement agreement to issue 5 million shares at a price of HKD 20.0 per share, representing approximately 2.25% of the existing shares as of the announcement date [1] - The placement price of HKD 20.0 is a discount of about 10.95% compared to the last closing price of HKD 22.46 on August 15, 2025 [1] Group 2 - The expected net proceeds from the placement, after deducting related costs, will be approximately HKD 99 million [2] - About 60% of the net proceeds will be used to repay existing interest-bearing bank loans, which have increased due to additional borrowings for R&D expenses, thereby improving the company's financial position [2] - Approximately 30% of the net proceeds will be allocated for the development of new pipelines, including QX027N, QX031N, and QX035N [2] - The remaining 10% of the net proceeds will be used for working capital and other corporate purposes [2]
荃信生物-B(02509)拟折让约10.95%配售500万股配售股份 净筹约9900万港元